Understanding Capsid Assembly and Genome Packaging for Adeno-Associated Viruses
Open accessAbstract
Adeno-associated viruses (AAVs) are promising therapeutic viral vectors. Their capsid is assembled from viral proteins VP1, VP2 and VP3, aided by an assembly-activating protein, followed by replication protein mediated packaging of their 4.7-kb genome with inverted terminal repeats as packaging signals. To aid improvement of AAV vectors, knowledge of viral determinants of successful capsid assembly and genome packaging is important. We review the current knowledge of these two processes and efforts to overcome limited DNA packaging capacity and limit the packaging of unwanted foreign DNA in vector development. Residues involved in essential capsid assembly and genome packaging interactions cannot be manipulated in vector engineering. This information thus aids strategies to improve vector production and to increase AAV packaging capacity toward improved efficacy of this vector system.
AI snapshot
Written from the paper’s full text.
TL;DR
This review summarizes current knowledge of adeno-associated virus (AAV) capsid assembly and genome packaging, focusing largely on AAV2, and discusses how these processes inform vector engineering. It highlights essential viral determinants, packaging limits, and strategies to overcome them.
Key findings
- AAV capsids are assembled from 60 subunits of VP1:VP2:VP3 in an approximate 1:1:10 ratio, with T = 1 icosahedral symmetry and a diameter of approximately 260 Å, packaging a linear ssDNA genome of approximately 4.7 kb flanked by approximately 150-nucleotide ITRs.
- VP3 common sequence is sufficient to assemble capsids when VP1 and VP2 start codons are knocked out, but the assembly-activating protein (AAP) is essential for most tested serotypes except AAV4, AAV5, and AAV11; two- and fivefold interfaces are important for assembly, while the threefold interface appears redundant.
- Genome packaging requires small Rep proteins (Rep52/40), with large Rep proteins (Rep78/68) needed for replication; packaging is coupled to replication, and ssDNA is translocated 3′ to 5′ through the fivefold channel. Mutations such as T329/T330A and R432A reduce or prevent packaging.
- Packaging is most efficient for genomes of 4.1–4.9 kb, with an upper threshold at 5.2 kb; self-complementary AAV vectors reduce coding capacity by approximately 50% to about 2.5 kb, while oversized, dual, trans-splicing, and miniaturized gene strategies are used for larger genes.
Methods
- Narrative review synthesizing published structural, mutational, biochemical, and vector-development studies, with most research conducted on AAV2 and therefore the focus of the review.
- Evidence drawn from x-ray crystallography and cryo-electron microscopy structures, mutagenesis, pulse-chase experiments, sedimentation analysis, mass spectrometry, and packaging assays; no new experimental data are reported.
- Main analysis is qualitative synthesis, including tables and figures of residues and interactions involved in capsid assembly and genome packaging.
Limitations
- The paper states several open questions: the temporal order of dimer and pentamer formation, exact roles of nucleolin and nucleophosmin, the reason for serotype-specific AAP requirements, Rep determinants and capsid footprint, additional host factors, and whether the conserved internal nucleotide-binding pocket affects packaging or stability.
- Evident from the text: the review is not systematic and is heavily focused on AAV2, limiting generalization to other AAV serotypes; it also relies on cited studies rather than presenting primary data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
21 of 57 cited sources checked · 8 supported · 1 flagged · accuracy not yet measured
- Premisecitation
All serotypes tested, with the exception of AAV4, AAV5 and AAV11, require AAP in order to assemble their capsid.
“In the most recent studies, it has been shown that all serotypes tested, with the exception of AAV4, AAV5 and AAV11, require AAP in order to assemble their capsid [35,39, 45–47].”
Quote in the paperSubstantial claim3 of 5 sources checked- cites [35] Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc. Natl Acad. Sci. USA 107(22), 10220– 10225 (2010). 20479244 PMC2890453 • The discovery of assembly-activating protein settled a decade-long controversy about which VP is essential for capsid assembly and the identification and characterization of the AAV scaffold protein. source
The Results and Discussion show that AAP is required for AAV2 capsid assembly. The paper does not establish that all tested serotypes require AAP or identify AAV4, AAV5, and AAV11 as exceptions; its discussion of other serotypes concerns sequence conservation, not assembly requirements. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [39] Naumer M, Sonntag F, Schmidt K Properties of the adeno-associated virus assembly-activating protein. J. Virol 86(23), 13038– 13048 (2012). 23015698 PMC3497687 source
- cites [45] Earley LF, Powers JM, Adachi K Adeno-associated virus assembly-activating protein is not an essential requirement for capsid assembly of AAV serotypes 4, 5 and 11. J. Virol 85(23), 12686– 12697 (2016). PMC5244341 27852862 source
- cites [46] Sonntag F, Kother K, Schmidt K The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes. J. Virol 85(23), 12686– 12697 (2011). 21917944 PMC3209379 source
The paper’s Results report that AAV5-VP3 capsid formation was restored by AAP-5, and its summary explicitly says AAV5 assembly required AAP-5. Thus AAV5 is not an exception to AAP dependence in this source. The paper discusses AAV4 and AAV11 sequence differences but does not test their assembly requirement. (LLM, conf=0.92)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured - cites [47] Popa-Wagner R, Sonntag F, Schmidt K, King J, Kleinschmidt JA. Nuclear translocation of adeno-associated virus type 2 capsid proteins for virion assembly. J. Gen. Virol 93(Pt 9), 1887– 1898 (2012). 22694902 source
- Premisecitation
The cytoplasmic fraction contains VP monomers and oligomers ranging from 10 to 15S, consistent with trimers and pentamers of VP1, VP2 and VP3.
“Sedimentation sucrose gradient analysis of nuclear and cytoplasmic fractions of an AAV infection demonstrated that the cytoplasmic fraction contains a population of VP monomers and oligomers ranging in size from 10 to 15S consistent with the sedimentation coefficients for trimers and pentamers, respectively, of VP1, VP2 and VP3.”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [27] Wistuba A, Weger S, Kern A, Kleinschmidt JA. Intermediates of adeno-associated virus type 2 assembly: identification of soluble complexes containing Rep and Cap proteins. J. Virol 69(9), 5311– 5319 (1995). 7636974 PMC189369 source
The Results (Fig. 3a–b; page not provided) report cytoplasmic VP monomers around 6.5S and a continuous distribution of VP1, VP2 and VP3 oligomers extending to 19S. The distinct 10–15S peak and the tentative pentamer interpretation instead concern nuclear VP2/VP3 oligomers; the paper does not identify cytoplasmic oligomers as trimers and pentamers. (LLM, conf=0.88)
Experimental — accuracy not yet measured
- Premisecitation
Nucleolin and nucleophosmin associate with both VPs and assembled capsids in the nucleoli.
“Additionally, two nuclear proteins, nucleolin and nucleophosmin [43,44], have been shown to associate with both VPs and assembled capsids in the nucleoli.”
Quote in the paperNot a substantial claim2 of 2 sources checked- cites [43] Bevington JM, Needham PG, Verrill KC, Collaco RF, Basrur V, Trempe JP. Adeno-associated virus interactions with B23/Nucleophosmin: identification of sub-nucleolar virion regions. Virology 357(1), 102– 113 (2007). 16959286 PMC1829415 source
The ‘NPM co-localization with Cap and Rep proteins’ section reports that nucleophosmin (NPM) co-localizes with AAV Cap proteins in nucleoli. The Discussion proposes a model in which Cap proteins assemble there and associate with NPM, but the paper does not establish an association with assembled capsids; it also does not address nucleolin. (LLM, conf=0.87)
Experimental — accuracy not yet measured - cites [44] Qiu J, Brown KE. A 110-kDa nuclear shuttle protein, nucleolin, specifically binds to adeno-associated virus type 2 (AAV-2) capsid. Virology 257(2), 373– 382 (1999). 10329548 source
The Discussion (page unavailable) describes nucleolin binding to VP1 and VP2 and proposes that it may direct them to the nucleolus. The results section reports nucleolin coimmunoprecipitating with assembled capsids and colocalizing with them in the nucleus, while the Discussion says capsid assembly occurs in the nucleolus. The paper does not demonstrate that both associations occur specifically in the nucleoli; it addresses nucleolin, not the separately cited nucleophosmin. (LLM, conf=0.82)
Experimental — accuracy not yet measured
- Premisecitation
By replacing the D-sequence in one of the flanking ITRs with an unrelated sequence, packaging of genomes with only positive or negative polarity can be achieved.
“By replacing the D-sequence in one of the flanking ITRs with an unrelated sequence, the packaging of genomes with only positive or negative polarity can be achieved [49].”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [49] Ling C, Wang Y, Lu Y Enhanced transgene expression from recombinant single-stranded D-sequence-substituted adeno-associated virus vectors in human cell lines in vitro and in murine hepatocytes in vivo. J. Virol 89(2), 952– 961 (2015). 25355884 PMC4300666 source
- Premisecitation
Different types of contaminating DNA sequences, including fragments of the host cell genome from vector production cells, are copackaged with transgenes in AAV vectors.
“different types of contaminating DNA sequences have been described as being copackaged with the transgenes, including fragments of the host cell genome from the cells that are used during vector production [81].”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [81] Levy HC, Bowman VD, Govindasamy L Heparin binding induces conformational changes in Adeno-associated virus serotype 2. J. Struct. Biol 165(3), 146– 156 (2009). 19121398 PMC3694330 source
The Results and Discussion section ('AAV2-Hep encapsidates an ordered, dodecahedral cage of DNA'; page unavailable) reports non-viral DNA inside AAV2 virus-like particles and suggests that random DNA fragments may be packaged during assembly. It does not identify those fragments as host-cell genomic DNA or show them copackaged with transgenes in AAV vectors; the particles studied lacked a viral genome. (LLM, conf=0.85)
Experimental — accuracy not yet measured
- Premisecitation
AAP functions as a scaffold protein that facilitates the localization of VP3 to the nucleus.
“The AAP is reported to function as a scaffold protein that facilitates the localization of VP3 to the nucleus [35].”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [35] Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc. Natl Acad. Sci. USA 107(22), 10220– 10225 (2010). 20479244 PMC2890453 • The discovery of assembly-activating protein settled a decade-long controversy about which VP is essential for capsid assembly and the identification and characterization of the AAV scaffold protein. source
The Results report that coexpressing AAP moves some VP3 into the nucleolus, a region within the nucleus. The Discussion says AAP *could* act as a scaffold during capsid assembly, but presents that as one possible mechanism, not an established function. The claim overstates the scaffold role and describes nucleolar targeting less precisely as nuclear localization. (LLM, conf=0.88)
Experimental — accuracy not yet measured
- Premisecitation
Residues located at the two- and fivefold interfaces of the VP, secondary structure elements, and close to the fivefold channel play a role in capsid assembly.
“Residues located at the two- and fivefold interfaces of the VP, secondary structure elements and close to the fivefold channel play a role in capsid assembly (Table 1 & Figure 4) [36–37].”
Quote in the paperSubstantial claim1 of 2 sources checked- cites [36] Bleker S, Sonntag F, Kleinschmidt JA. Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity. J. Virol 79(4), 2528– 2540 (2005). 15681453 PMC546590 source
The Discussion (page unavailable) reports that mutations in the VP beta-barrel impaired assembly and that several mutations near the fivefold pore impaired or abolished capsid formation. It does not establish a role in assembly for residues at the twofold interface; its mention of twofold axes concerns the location of VP N termini, not assembly. (LLM, conf=0.87)
Experimental — accuracy not yet measured - cites [37] Popa-Wagner R, Porwal M, Kann M Impact of VP1-specific protein sequence motifs on adeno-associated virus type 2 intracellular trafficking and nuclear entry. J. Virol 86(17), 9163– 9174 (2012). 22696661 PMC3416132 source
- Premisecitation
The nuclear fraction contained VP oligomers with sedimentation coefficients between 60 and 110S, consistent with empty and full capsids, respectively.
“The nuclear fraction contained VP oligomers with sedimentation coefficients between 60 and 110S consistent with empty and full capsids, respectively [27].”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [27] Wistuba A, Weger S, Kern A, Kleinschmidt JA. Intermediates of adeno-associated virus type 2 assembly: identification of soluble complexes containing Rep and Cap proteins. J. Virol 69(9), 5311– 5319 (1995). 7636974 PMC189369 source
- Premisecitation
In addition to VP3, the assembly-activating protein (AAP) is also essential for capsid assembly.
“However, in addition to VP3, the AAP is also essential for capsid assembly [35].”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [35] Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc. Natl Acad. Sci. USA 107(22), 10220– 10225 (2010). 20479244 PMC2890453 • The discovery of assembly-activating protein settled a decade-long controversy about which VP is essential for capsid assembly and the identification and characterization of the AAV scaffold protein. source
- Premisecitation
For the majority of rAAV vectors, the ITRs and rep gene of AAV2 are utilized, resulting in pseudotyped rAAVs.
“For the majority of rAAV vectors, the ITRs and rep gene of serotype 2 (AAV2) are utilized resulting in pseudo-typed rAAVs [11].”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [11] Grimm D, Kay MA, Kleinschmidt JA. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol. Ther 7(6), 839– 850 (2003). 12788658 source
The Results describe pseudotyped particles containing AAV-2 vector DNA made with a helper that retains AAV-2 rep while substituting capsid genes from other serotypes. The Discussion says pseudotyping of non-type-2 vectors had been described only once, supporting the prominence of AAV-2-based pseudotyping. Neither passage establishes that the majority of all rAAV vectors use AAV-2 ITRs and rep or that most rAAV vectors are pseudotyped. (LLM, conf=0.78)
Experimental — accuracy not yet measured
- Premisecitation
Recent next-generation sequencing based technologies allow unbiased identification and quantification of DNA impurities.
“Recent next-generation sequencing based technologies allow an unbiased identification and quantification of DNA impurities [87].”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [87] Lecomte E, Tournaire B, Cogne B Advanced characterization of DNA molecules in rAAV vector preparations by single-stranded virus next-generation sequencing. Mol. Ther. Nucleic Acids 4, e260 (2015). 26506038 PMC4881760 • Characterized the contamination of purified AAV vector preparation with packaged nonvector DNAs using next-generation sequencing. source
The Results section (‘Distribution of DNA contaminants identified by NGS correlates with qPCR data’; page not specified) reports relative proportions of contaminants measured by SSV-Seq, while the Introduction explains that it avoids qPCR’s need for target-specific assays. But the Discussion (page not specified) warns that uneven amplification can introduce quantitative bias into NGS data, so ‘unbiased’ quantification overstates the source. (LLM, conf=0.87)
Experimental — accuracy not yet measured
- Premisecitation
Mutational studies on the entire cap gene showed that the VP3 common sequence is enough to assemble AAV capsids by knocking out the start codons of VP1 and VP2.
“Mutational studies on the entire cap gene showed that the VP3 common sequence is enough to assemble AAV capsids by knocking out the start codons of VP1 and VP2 [31–34].”
Quote in the paperNot a substantial claim1 of 4 sources checked- cites [31] Ruffing M, Zentgraf H, Kleinschmidt JA. Assembly of viruslike particles by recombinant structural proteins of adeno-associated virus type 2 in insect cells. J. Virol 66(12), 6922– 6930 (1992). 1331503 PMC240317 source
- cites [32] Steinbach S, Wistuba A, Bock T, Kleinschmidt JA. Assembly of adeno-associated virus type 2 capsids in vitro. J. Gen. Virol 78 (Pt 6) 1453– 1462 (1997). 9191943 source
- cites [33] Rabinowitz JE, Xiao W, Samulski RJ. Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology 265(2), 274– 285 (1999). 10600599 source
- cites [34] Warrington KH Jr, Gorbatyuk OS, Harrison JK, Opie SR, Zolotukhin S, Muzyczka N. Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J. Virol 78(12), 6595– 6609 (2004). 15163751 PMC416546 source
- Premisecitation
For productive replication, AAVs depend on coinfection with helper viruses such as adenoviruses or herpesviruses.
“For productive replication, the AAVs depend on the coinfection with helper viruses, such as, adenoviruses or herpesviruses [2].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [2] Weitzman MD, Linden RM. Adeno-associated virus biology. Methods Mol. Biol 807, 1– 23 (2011). 22034024 source
- Premisecitation
The viral capsid is assembled from the overlapping VP3 region.
“The viral capsid is assembled from the overlapping VP3 region [8].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [8] Mclaughlin SK, Collis P, Hermonat PL, Muzyczka N. Adeno-associated virus general transduction vectors: analysis of proviral structures. J. Virol 62(6), 1963– 1973 (1988). 2835501 PMC253280 source
- Premisecitation
Helper viruses provide transcription factors for AAV promoters, replication factors, and factors that modify the host cell environment for efficient AAV transcription, translation and genome replication.
“The functions that these helper viruses provide include transcription factors for the AAV promoters, replication factors and factors that modify the host cell environment for efficient AAV transcription, translation and genome replication [2].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [2] Weitzman MD, Linden RM. Adeno-associated virus biology. Methods Mol. Biol 807, 1– 23 (2011). 22034024 source
- Premisecitation
VP1 contains a phospholipase A2 site in its unique N-terminus (VP1u) that is important for endo/lysosomal escape during cellular trafficking and viral infectivity.
“VP1 is encoded within the entire cap ORF, it is approximately 735 aa in length, 87 kDa in molecular weight (MW) and contains a phospholipase A2 (PLA2) site that is important for endo/lysosomal escape during cellular trafficking and viral infectivity in its unique N-terminus (VP1u) [7].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [7] Girod A, Wobus CE, Zadori Z The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J. Gen.Virol 83(Pt 5), 973– 978 (2002). 11961250 source
- Premisecitation
Mutation of the D-sequence region in both ITRs leads to a defect in replication and packaging.
“Mutation of this region in both ITRs leads to a defect in replication and packaging [50].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [50] Wang XS, Qing K, Ponnazhagan S, Srivastava A. Adeno-associated virus type 2 DNA replication in vivo: mutation analyses of the D sequence in viral inverted terminal repeats. J. Virol 71(4), 3077– 3082 (1997). 9060669 PMC191438 source
- Premisecitation
Assembled capsids are first detected in the nucleus, specifically in the nucleoli during a productive infection.
“Assembled capsids are first detected in the nucleus, specifically in the nucleoli during a productive infection [26].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [26] Wistuba A, Kern A, Weger S, Grimm D, Kleinschmidt JA. Subcellular compartmentalization of adeno-associated virus type 2 assembly. J. Virol 71(2), 1341– 1352 (1997). 8995658 PMC191189 source
- Premisecitation
Increasing the backbone of the vector genome plasmid to sizes larger than the packaging capacity of AAV vectors minimizes reverse packaging.
“the increase of the backbone of the vector genome plasmid to sizes larger than the packaging capacity of AAV vectors to minimize reverse packaging [86]”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [86] Hauck B, Murphy SL, Smith PH Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses. Mol. Ther 17(1), 144– 152 (2009). 18941440 PMC2834997 source
- Interpretationreasoning
Alterations of residues in the symmetry-related interfaces are predicted to abrogate the formation of assembly intermediates or building blocks that are important components of the assembly pathway.
“Alterations of residues in the symmetry-related interfaces are predicted to abrogate the formation of assembly intermediates or building blocks that are important components of the assembly pathway.”
Quote in the paperSubstantial claim - Premisenone given
For AAVs, specific regions of the capsid, including the two- and fivefold interfaces, have been identified as important determinants of assembly.
“For the AAVs, specific regions of the capsid have been identified as important determinants of assembly, including the two- and fivefold interfaces.”
Quote in the paperSubstantial claim - Premisecitation
In recombinant AAV vectors, a desired transgene expression cassette is packaged into the capsids instead of the wild-type viral genome.
“In recombinant AAV vectors (rAAVs), a desired transgene expression cassette is packaged into the capsids instead of the wild-type (WT) viral genome [10].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [10] Gray JT, Zolotukhin S. Design and construction of functional AAV vectors. Methods Mol. Biol 807, 25– 46 (2011). 22034025 source
- Premisenone given
For packaging of a DNA molecule into AAV capsids, the DNA sequence must be flanked by the cis-acting ITRs.
“For the packaging of a certain DNA molecule into AAV capsids, the WT AAV genome or any transgene cassette, the DNA sequence must be flanked by the cis-acting ITRs.”
Quote in the paperSubstantial claim - Interpretationnone given
The translocation of the ssDNA into the capsid is believed to occur through the channel at the fivefold symmetry axis.
“The translocation of the ssDNA into the capsid is believed to occur through the channel at the fivefold symmetry axis.”
Quote in the paperNot a substantial claim - Premisecitation
Single-stranded binding proteins E2A (adenovirus) or ICP8 (herpes virus) provided by helper viruses are involved in displacement of the ssDNA genome.
“In that process, the single-stranded binding proteins, E2A (adenovirus) or ICP8 (herpes virus) provided by the helper viruses are involved [2, 51].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [2] Weitzman MD, Linden RM. Adeno-associated virus biology. Methods Mol. Biol 807, 1– 23 (2011). 22034024 source
- cites [51] Alex M, Weger S, Mietzsch M, Slanina H, Cathomen T, Heilbronn R. DNA-binding activity of adeno-associated virus Rep is required for inverted terminal repeat-dependent complex formation with herpes simplex virus ICP8. J. Virol 86(5), 2859– 2863 (2012). 22205745 PMC3302247 source
- Interpretationcitation
The current model for AAV packaging couples the replication and packaging process.
“The current model for AAV packaging couples the replication and packaging process (Figure 5A).”
Quote in the paperNot a substantial claim - Premisenone given
The T=1 icosahedral capsid of AAVs is assembled via two-, three- and fivefold interactions which form a dimer, trimer and pentamer, respectively.
“The T = 1 icosahedral capsid of the AAVs (Figure 2B) is assembled via two-, three- and fivefold interactions which form a dimer, trimer and pentamer, respectively (Figure 3).”
Quote in the paperNot a substantial claim - Premisecitation
Removal of potential RBEs from helper constructs reduces packaging of nonvector DNA sequences.
“the removal of potential RBEs from helper constructs [85]”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [85] Mietzsch M, Casteleyn V, Weger S, Zolotukhin S, Heilbronn R. OneBac 2.0: Sf9 cell lines for production of AAV5 vectors with enhanced infectivity and minimal encapsidation of foreign DNA. Hum. Gene Ther 26(10), 688– 697 (2015). 26134901 PMC4842952 source
- Premisecitation
The Rep proteins, capsids and the AAV DNA colocalize in the nucleoplasm in infected cells.
“This is supported by the observation that the Rep proteins, capsids and the AAV DNA colocalize in the nucleoplasm in infected cells [26].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [26] Wistuba A, Kern A, Weger S, Grimm D, Kleinschmidt JA. Subcellular compartmentalization of adeno-associated virus type 2 assembly. J. Virol 71(2), 1341– 1352 (1997). 8995658 PMC191189 source
- Premisereasoning
Helper gene constructs transfected or infected into vector producer cells are a source of DNA impurities in AAV vector preparations.
“Another source of DNA impurities are the helper gene constructs that are transfected or infected into the vector producer cells.”
Quote in the paperNot a substantial claim - Premisecitation
Reverse packaging results in the packaging of DNA sequences outside of the ITR-flanked vector genome cassette.
“Third, a phenomenon termed ‘reverse packaging’ has been described that results in the packaging of DNA sequences outside of the ITR-flanked vector genome cassette [84].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [84] Wright JF. Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther. 15(11), 840– 848 (2008). 18418418 source
- Interpretationreasoning
Dimer and pentamer formation are important steps in AAV capsid assembly.
“This suggests that dimer and pentamer formation are important steps in this process, although further studies are required to determine their temporal order.”
Quote in the paperSubstantial claim - Premisereasoning
Quantitative PCR limits quantification of foreign DNA contamination to sequences specifically detected by primers of known sequences.
“However, this limits the quantification to only those sequences that are specifically detected by primers of known sequences.”
Quote in the paperSubstantial claim - Premisereasoning
The VP3 of AAV4, AAV5 and AAV11 enter the nucleus via an AAP-independent mechanism that is yet unknown.
“Thus, the VP3 of these exceptions (AAV4, AAV5 and AAV11) enter the nucleus via an AAP-independent mechanism that is yet unknown and challenge what is known about the role of AAP in AAV capsid assembly.”
Quote in the paperNot a substantial claim - Premisecitation
After one single-stranded genome is fully displaced, the DNA is translocated into the capsid in a 3′ to 5′ direction by the helicase/ATPase domain of the small Rep proteins.
“After one single-stranded genome is fully displaced, the DNA is reported to be translocated into the capsid in a 3′ to 5′ direction by the helicase/ATPase domain of the small Rep proteins [53].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [53] King JA, Dubielzig R, Grimm D, Kleinschmidt JA. DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. Embo. J 20(12), 3282– 3291 (2001). 11406604 PMC150213 source
- Interpretationreasoning
Fidelity of the interactions between viral components dictates the ITR-mediated packaging of WT genomes as well as transgenes into AAV capsids.
“Fidelity of the interactions between these viral components dictate the ITR-mediated packaging of WT genomes as well as transgenes into AAV capsids.”
Quote in the paperSubstantial claim - Premisecitation
Genome sequences closely homologous to RBE, such as the AAVS1 site, have been detected in purified AAV vector preparations.
“It has been reported that genome sequences which are close homologs to RBE, such as, the AAVS1 site, were detected in purified AAV vector preparations [82].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [82] Hüser D, Weger S, Heilbronn R. Packaging of human chromosome 19-specific adeno-associated virus (AAV) integration sites in AAV virions during AAV wild-type and recombinant AAV vector production. J. Virol 77(8), 4881– 4887 (2003). 12663794 PMC152110 source
- Premisecitation
Herpes virus directly interacts with AAV replication with its viral helicase-primase complex.
“Furthermore, herpes virus directly interacts with AAV replication with its viral helicase– primase complex [2].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [2] Weitzman MD, Linden RM. Adeno-associated virus biology. Methods Mol. Biol 807, 1– 23 (2011). 22034024 source
- Premisenone given
The fivefold axis contains a cylindrical channel formed by the interaction of five DE loops.
“The fivefold axis contains a cylindrical channel formed by the interaction of five DE loops (β-ribbons; Figure 3C).”
Quote in the paperNot a substantial claim
- May combine two claims. 24
- Classified as probably not a substantial claim. 10
May combine two claims.
PremisecitationThe virus capsid protects the viral genome, determines tissue tropism, and remains intact while it escapes the endo/lysosomal pathway and traffics to the nucleus where the genome is released.
“The virus capsid is a critical component of its infectious lifecycle: it protects the viral genome, determines the tissue type that is targeted (tissue tropism) or treated, and remains intact while it escapes the endo/lysosomal pathway and traffics to the nucleus where the genome is released [9]”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [9] Nonnenmacher M, Weber T. Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther. 19(6), 649– 658 (2012). 22357511 PMC4465241 source
The Introduction (page unavailable) links AAV serotypes to different tissue tropisms, and Cellular Barriers to AAV Transduction and Nuclear Import (pages unavailable) describe escape followed by probable import of intact particles and DNA release after nuclear entry. The paper says the capsid contains the genome, but does not explicitly say it protects it; it also presents intact-particle nuclear import as likely rather than certain. (LLM, conf=0.85)
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationThe twofold region has the least number of VP-VP interface interactions and represents the thinnest region of the virus capsid shell.
“This region has the least number of VP–VP interface interactions and represents the thinnest region of the virus capsid shell [23,24].”
Quote in the paperNot a substantial claim1 of 2 sources checked- cites [23] Govindasamy L, Padron E, Mckenna R Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J. Virol 80(23), 11556– 11570 (2006). 16971437 PMC1642620 • One of the main papers describing the structure of the adeno-associated virus (AAV) 4 capsid, comparing it with other serotypes, defining conserved and variable regions between these serotypes and correlating it to the capsid function. source
- cites [24] Agbandje-Mckenna M, Kleinschmidt J. AAV capsid structure and cell interactions. Methods Mol. Biol 807 47– 92 (2011). 22034026 source
May combine two claims.
PremisecitationThe threefold protrusions are formed from interdigitating loops from two VPs and have the most extensive VP-VP interactions.
“These protrusions are formed from interdigitating loops from two VPs and have the most extensive VP–VP interactions [23,24].”
Quote in the paperNot a substantial claim1 of 2 sources checked- cites [23] Govindasamy L, Padron E, Mckenna R Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J. Virol 80(23), 11556– 11570 (2006). 16971437 PMC1642620 • One of the main papers describing the structure of the adeno-associated virus (AAV) 4 capsid, comparing it with other serotypes, defining conserved and variable regions between these serotypes and correlating it to the capsid function. source
- cites [24] Agbandje-Mckenna M, Kleinschmidt J. AAV capsid structure and cell interactions. Methods Mol. Biol 807 47– 92 (2011). 22034026 source
May combine two claims.
PremisecitationMass spectrometry analysis of AAV1 showed that incorporation of VP1, VP2 and VP3 into the virus capsid was stochastic and likely related to the rate of expression of each VP.
“More recently, mass spectrometry analysis of AAV1 by an orbitrap mass spectrometer showed that the incorporation of VP1, VP2 and VP3 into the virus capsid was stochastic and likely related to the rate of expression of each VP [30].”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [30] Snijder J, van de Waterbeemd M, Damoc E Defining the stoichiometry and cargo load of viral and bacterial nanoparticles by Orbitrap mass spectrometry. J. Am. Chem. Soc 136(20), 7295– 7299 (2014). 24787140 PMC4046769 source
May combine two claims.
PremisecitationAAP binds to AAV VP multimers across the twofold axis of symmetry at β strands located at the inner surface of the capsid and targets these VPs to the nucleus where it facilitates capsid assembly.
“AAP was reported to bind to the AAV VP multimers across the twofold axis of symmetry (thus, a dimer interface) at the β strands located at the inner surface of the capsid and target these VPs to the nucleus where it facilitates capsid assembly [35].”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [35] Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc. Natl Acad. Sci. USA 107(22), 10220– 10225 (2010). 20479244 PMC2890453 • The discovery of assembly-activating protein settled a decade-long controversy about which VP is essential for capsid assembly and the identification and characterization of the AAV scaffold protein. source
The Results (page unavailable) show that AAP directs VP3 to nucleoli and promotes capsid formation. The Discussion (page unavailable) says the mechanism of AAP-mediated assembly remains elusive; our copy does not establish that AAP binds VP multimers at the twofold-axis dimer interface or at β strands on the capsid’s inner surface. (LLM, conf=0.90)
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationDuring AAV replication, the N-terminus of the large Rep proteins binds specifically to the RBE within the ITRs and cleaves the trs, which allows self-priming and induces further replication.
“During AAV replication, the N-terminus of the large Rep proteins (Table 2 & Figure 6A) [51] bind specifically to the RBE within the ITRs and cleave the trs [52] which allows self-priming and induces further replication.”
Quote in the paperNot a substantial claim1 of 2 sources checked- cites [51] Alex M, Weger S, Mietzsch M, Slanina H, Cathomen T, Heilbronn R. DNA-binding activity of adeno-associated virus Rep is required for inverted terminal repeat-dependent complex formation with herpes simplex virus ICP8. J. Virol 86(5), 2859– 2863 (2012). 22205745 PMC3302247 source
- cites [52] Im DS, Muzyczka N. Factors that bind to adeno-associated virus terminal repeats. J. Virol 63(7), 3095– 3104 (1989). 2542617 PMC250866 source
The Abstract identifies Rep78 and Rep68 as possible components of a complex that binds AAV terminal repeats, supporting the reference to the large Rep proteins. It does not locate binding in their N-terminus. The binding and cleavage clause is attached to citation [52], not the citation being audited. (LLM, conf=0.82)
Experimental — accuracy not yet measured
Probably not a substantial claim: may not pass S4 (based).
Interpretationnone givenResidues involved in essential capsid assembly and genome packaging interactions cannot be manipulated in vector engineering.
“Residues involved in essential capsid assembly and genome packaging interactions cannot be manipulated in vector engineering.”
Quote in the paperNot a substantial claimMay combine two claims.
Premisenone givenLarge Rep proteins Rep78/68 are indispensable for genome replication, while small Rep proteins Rep52/40 are essential for genome packaging.
“While the large Rep proteins, Rep78/68 are indispensable for genome replication, the small Rep proteins, Rep52/40 are essential for genome packaging.”
Quote in the paperSubstantial claimMay combine two claims.
Premisenone givenAAV capsid is assembled from VP1, VP2 and VP3, aided by an assembly-activating protein, followed by replication protein mediated packaging of their 4.7-kb genome with inverted terminal repeats as packaging signals.
“Their capsid is assembled from viral proteins VP1, VP2 and VP3, aided by an assembly-activating protein, followed by replication protein mediated packaging of their 4.7-kb genome with inverted terminal repeats as packaging signals.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationThe AAV capsid is composed of 60 subunits of overlapping VP1:VP2:VP3 in an approximate ratio of 1:1:10, assembled with T=1 icosahedral symmetry and a diameter of approximately 260 Å.
“The AAV capsid is composed of 60 subunits of the overlapping VP1:VP2:VP3, in an approximate ratio of 1:1:10, assembled with T = 1 icosahedral symmetry and a diameter of approximately 260 Å [13,14].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [13] Chapman MS, Agbandje-Mckenna M. Atomic structure of viral particles.In: Parvoviruses. Bloom ME, Linden RM, Parrish CR, Kerr JR (Eds). Edward Arnold, Ltd, London, UK, 109– 123 (2006).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [14] Buller RM, Rose JA. Characterization of adenovirus-associated virus-induced polypeptides in KB cells. J. Virol 25(1), 331– 338 (1978). 621779 PMC353931 source
May combine two claims.
PremisecitationCapsids colocalize with both Rep proteins and the ssDNA.
“This is followed by the observation of capsids colocalizing with both Rep proteins and the ssDNA [26, 41–42].”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [26] Wistuba A, Kern A, Weger S, Grimm D, Kleinschmidt JA. Subcellular compartmentalization of adeno-associated virus type 2 assembly. J. Virol 71(2), 1341– 1352 (1997). 8995658 PMC191189 source
- cites [41] Hunter LA, Samulski RJ. Colocalization of adeno-associated virus Rep and capsid proteins in the nuclei of infected cells. J. Virol 66(1), 317– 324 (1992). 1370086 PMC238290 source
- cites [42] Bleker S, Pawlita M, Kleinschmidt JA. Impact of capsid conformation and Rep-capsid interactions on adeno-associated virus type 2 genome packaging. J. Virol 80(2), 810– 820 (2006). 16378983 PMC1346863 source
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationThe AAV VP monomer N-terminus is not seen in crystal structures but has been suggested to be located on the inside of the capsid by cryo-reconstruction.
“The AAV VP monomer N-terminus (VP1u, VP1/2 common region, and ~15 VP3 N-terminal residues) is not seen in the crystal structures but has been suggested to be located on the inside of the capsid by cryo-reconstruction [21].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [21] Kronenberg S, Bottcher B, Von Der Lieth CW, Bleker S, Kleinschmidt JA. A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J. Virol 79(9), 5296– 5303 (2005). 15827144 PMC1082756 source
Probably not a substantial claim: may not pass S4 (based).
Interpretationnone givenThe threefold interface, with its numerous interactions, appears to be redundant in AAV capsid assembly.
“The threefold interface, with its numerous interactions, appears to be redundant in this process.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationRep expression cassettes driven by the AAV p5 promoter result in significant rep gene copackaging, possibly due to a cryptic RBE in the p5 promoter.
“Rep expression cassettes, driven by the AAV p5 promoter, have been reported to result in significant rep gene copackaging possibly due to the presence of a cryptic RBE in the p5 promoter [83].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [83] Nony P, Chadeuf G, Tessier J, Moullier P, Salvetti A. Evidence for packaging of rep-cap sequences into adeno-associated virus (AAV) type 2 capsids in the absence of inverted terminal repeats: a model for generation of rep-positive AAV particles. J. Virol 77(1), 776– 781 (2003). 12477885 PMC140600 source
May combine two claims.
Premisenone givenThe channel connects the inside of the viral capsid to the outside and is reported to be the site of genome packaging and uncoating, and VP1u externalization for its PLA2 function required for endo/lysosomal capsid escape en route to the nucleus.
“The channel connects the inside of the viral capsid to the outside and is reported to be the site of genome packaging and uncoating, and VP1u externalization for its PLA2 function required for endo/lysosomal capsid escape en route to the nucleus.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S2 (checkable).
InterpretationreasoningFurther knowledge of AAV determinants for capsid assembly and genome packaging provides important guides for vector engineering.
“Further knowledge of AAV determinants for capsid assembly and genome packaging provide important guides for vector engineering.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationThe products of replication are DNA genomes of positive and negative polarity that are packaged into AAV virions with equal frequency.
“The products of the replication are DNA genomes of positive and negative polarity that are packaged into the AAV virions with equal frequency [48].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [48] Mayor HD, Torikai K, Melnick JL, Mandel M. Plus and minus single-stranded DNA separately encapsidated in adeno-associated satellite virions. Science 166(3910), 1280– 1282 (1969). 5350322 source
Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Premisenone givenNuclear proteins, particularly nucleolin and nucleophosmin, are involved in AAV capsid assembly.
“Nuclear proteins, particularly nucleolin and nucleophosmin, are involved in this assembly process, although their exact role requires further elucidation.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S4 (based).
Premisenone givenWith respect to genome packaging, the Rep proteins and VPs, particularly the VP3 overlapping sequence, play a role.
“With respect to genome packaging, the Rep proteins and VPs, particularly the VP3 overlapping sequence, play a role.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Interpretationnone givenChanges in the secondary structure elements of the VPs are likely to cause misfolding and ultimately degradation by the ubiquitin/proteasomal pathway.
“Changes in the secondary structure elements of the VPs are likely to cause misfolding and ultimately degradation by the ubiquitin/proteasomal pathway.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim. May combine two claims.
InterpretationreasoningThis knowledge is particularly useful in efforts to generate vector variants with improved transduction efficiency, improved vector production, and packaging of transgenes with oversized genomes.
“This is particularly useful in efforts to generate vector variants with the desired phenotypes of improved transduction efficiency in addition to improved vector production and the packaging of transgenes with oversized genomes.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationThe pulse-chase experiment by Myers and Carter showed that AAV capsid assembly involves rapid formation of empty capsids from a pool of VPs, followed by the slow rate limiting step of packaging the ssDNA genome into the preformed empty capsid.
“The first glimpse into the mechanism of AAV capsid assembly was provided by the pulse-chase experiment by Myers and Carter which showed that the process involves the rapid formation of empty capsids from a pool of VPs, followed by the slow rate limiting step of packaging the ssDNA genome into the preformed empty capsid (see next section) [25].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [25] Myers MW, Carter BJ. Assembly of adeno-associated virus. Virology 102(1), 71– 82 (1980). 6245509 • The first and only research to date that has shown that the mechanism of capsid assembly is a two-step process and that the packaging step is rate limiting. source
May combine two claims.
PremisecitationAAP is a 23-kDa protein encoded within the ORF of VP2 and VP3, initiated from a non-canonical CTG start codon, and translated in a different reading frame compared with the VP sequence.
“This 23-kDa protein is also encoded within the ORF of VP2 and VP3, initiated from a non-canonical CTG start codon, and translated in a different reading frame compared with the VP sequence.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim. May combine two claims.
InterpretationreasoningThese efforts can avoid the modification of essential residues while nonessential amino acid positions provide sites for engineering.
“These efforts can avoid the modification of essential residues while nonessential aa positions provide sites for engineering.”
Quote in the paperSubstantial claimMay combine two claims.
Premisenone givenThe ITRs represent packaging signals and also aid amplification of the DNA genome by a self-primed replication mechanism.
“These not only represent the packaging signals but also aid the amplification of the DNA genome by a self-primed replication mechanism (Figure 5A).”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationVP proteins are produced in the cytoplasm and transported to the nucleus, specifically to the nucleoli where capsid assembly occurs.
“Immunofluorescence and immunoprecipitation experiments have shown that the VP proteins are produced in the cytoplasm and are then transported to the nucleus, specifically to the nucleoli where capsid assembly occurs [26].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [26] Wistuba A, Kern A, Weger S, Grimm D, Kleinschmidt JA. Subcellular compartmentalization of adeno-associated virus type 2 assembly. J. Virol 71(2), 1341– 1352 (1997). 8995658 PMC191189 source
May combine two claims.
InterpretationcitationAssembled capsids have been detected in the nucleus in the absence of the replication proteins, suggesting that their presence is not required for assembly.
“However, assembled capsids have been detected in the nucleus in the absence of the replication proteins suggesting that their presence is not required for assembly.”
Quote in the paperNot a substantial claimMay combine two claims.
Interpretationnone givenEfficient capsid assembly and genome packaging are essential steps in wild-type AAV infection and in the production of vectors for therapeutic application.
“Efficient capsid assembly and genome packaging are essential steps in WT virus infection as well as the production of vectors for therapeutic application.”
Quote in the paperSubstantial claimMay combine two claims.
Premisenone givenThe AAV packaging process occurs in the nucleus of the cell producing the AAV capsid and relies on the presence of assembled empty capsids, replicated AAV genomes and the viral Rep proteins.
“The AAV packaging process occurs in the nucleus of the cell producing the AAV capsid and relies on the presence of: assembled empty capsids, replicated AAV genomes and the viral Rep proteins.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationTo construct rAAVs, only the flanking cis-active ITRs have to be retained for packaging of the transgene cassette while the rep and cap genes can be supplied in trans.
“To construct rAAVs, only the flanking cis-active ITRs have to be retained for the packaging of the transgene cassette while the rep and cap genes can be supplied in trans [10].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [10] Gray JT, Zolotukhin S. Design and construction of functional AAV vectors. Methods Mol. Biol 807, 25– 46 (2011). 22034025 source
The paper relies on this without support.
The packaging mechanisms of wild-type AAV capsids and recombinant AAV capsids are identical.
“Generally, it is believed that the packaging mechanisms of both types of AAV capsids are identical.”
The paper relies on this without support.
Contamination of AAV capsids with foreign DNA sequences is detrimental for clinical applications.
“For the clinical applications of AAV vectors, the capsids should ideally only contain the desired vector genome cassettes with none to minimal contaminations with foreign DNA sequences.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Two different papers have identical journal volume, issue, and pages
MinorReferences 45 and 46 assign the same journal volume, issue, and page range to different articles, with different publication years. Both citations cannot be correct as printed.
“45. Earley LF, Powers JM, Adachi K Adeno-associated virus assembly-activating protein is not an essential requirement for capsid assembly of AAV serotypes 4, 5 and 11. J. Virol 85(23), 12686– 12697 (2016).”
“46. Sonntag F, Kother K, Schmidt K The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes. J. Virol 85(23), 12686– 12697 (2011).”
Cites
Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · see citing works
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,025 · see citing works
McCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735 · see citing works
Quantitative analysis of the packaging capacity of recombinant adeno-associated virus
Dong, J.-Y., Fan, P.-D., & Frizzell, R. A. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.17-2101 · Cited by 583 · see citing works
Im, D., & Muzyczka, N. (1990) · Cell · doi:10.1016/0092-8674(90)90526-k · Cited by 466 · see citing works
Gray, S. J., Foti, S. B., Schwartz, J. W., Bachaboina, L., Taylor-Blake, B., Coleman, J., Ehlers, M. D., Zylka, M. J., McCown, T. J., & Samulski, R. J. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.245 · Cited by 420 · see citing works
Grieger, J. C., & Samulski, R. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9933-9944.2005 · Cited by 419 · see citing works
Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector
Bowles, D. E., McPhee, S. W., Li, C., Gray, S. J., Samulski, J. J., Camp, A. S., Li, J., Wang, B., Monahan, P. E., Rabinowitz, J. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.237 · Cited by 400 · see citing works
Self-citationA viral assembly factor promotes AAV2 capsid formation in the nucleolus
Sonntag, F., Schmidt, K., & Kleinschmidt, J. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001673107 · Cited by 392 · see citing works
Wu, P., Xiao, W. S., Conlon, T. J., Hughes, J. A., Agbandje‐McKenna, M., Ferkol, T. W., Flotte, T. R., & Muzyczka, N. (2000) · Journal of Virology · doi:10.1128/jvi.74.18.8635-8647.2000 · Cited by 390 · see citing works
Self-citationGirod, A., Wobus, C. E., Zádori, Z., Ried, M., Leike, K., Tijssen, P., Kleinschmidt, J. A., & Hallek, M. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-5-973 · Cited by 354 · see citing works
Adeno-associated virus general transduction vectors: analysis of proviral structures
McLaughlin, S. K., Collis, P., Hermonat, P. L., & Muzyczka, N. (1988) · Journal of Virology · doi:10.1128/jvi.62.6.1963-1973.1988 · Cited by 348 · see citing works
Grimm, D., Kay, M. A., & Kleinschmidt, J. A. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00095-9 · Cited by 344 · see citing works
DNA helicase‐mediated packaging of adeno‐associated virus type 2 genomes into preformed capsids
King, J. A., Dubielzig, R., Grimm, D., & Kleinschmidt, J. A. (2001) · The EMBO Journal · doi:10.1093/emboj/20.12.3282 · Cited by 338 · see citing works
Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy
Yan, Z., Zhang, Y., Duan, D., & Engelhardt, J. F. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6716 · Cited by 305 · see citing works
Allocca, M., Doria, M., Petrillo, M., Colella, P., Garcia-Hoyos, M., Gibbs, D., Kim, S. R., Maguire, A., Rex, T. S., Di Vicino, U., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34316 · Cited by 292 · see citing works
Effective delivery of large genes to the retina by dual AAV vectors
Trapani, I., Colella, P., Sommella, A., Iodice, C., Cesi, G., de Simone, S., Marrocco, E., Rossi, S., Giunti, M., Palfi, A., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302948 · Cited by 269 · see citing works
Intracellular transport of recombinant adeno-associated virus vectors
Nonnenmacher, M., & Weber, T. (2012) · Gene Therapy · doi:10.1038/gt.2012.6 · Cited by 258 · see citing works
Structure of Adeno-Associated Virus Serotype 8, a Gene Therapy Vector
Nam, H.-J., Lane, M. D., Padron, E., Gurda, B. L., McKENNA, R. V., Kohlbrenner, E., Aslanidi, G., Byrne, B. J., Muzyczka, N., Zolotukhin, S., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01304-07 · Cited by 256 · see citing works
Self-citationStructural insight into the unique properties of adeno-associated virus serotype 9
DiMattia, M. A., Nam, H.-J., Van Vliet, K., Mitchell, M., Bennett, A., Gurda, B. L., McKenna, R., Olson, N. H., Sinkovits, R. S., Potter, M., et al. (2012) · Journal of Virology · doi:10.1128/jvi.07232-11 · Cited by 219 · see citing works
Self-citationSubcellular compartmentalization of adeno-associated virus type 2 assembly
Wistuba, A., Kern, A., Weger, S., Grimm, D., & Kleinschmidt, J. A. (1997) · Journal of Virology · doi:10.1128/jvi.71.2.1341-1352.1997 · Cited by 219 · see citing works
AAV Capsid Structure and Cell Interactions
Agbandje-McKenna, M., & Kleinschmidt, J. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_3 · Cited by 215 · see citing works
Self-citationWarrington, K. H., Gorbatyuk, O. S., Harrison, J. K., Opie, S. R., Zolotukhin, S., & Muzyczka, N. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6595-6609.2004 · Cited by 205 · see citing works
Manufacturing and characterizing AAV-based vectors for use in clinical studies
Wright, J. F. (2008) · Gene Therapy · doi:10.1038/gt.2008.65 · Cited by 205 · see citing works
Structurally mapping the diverse phenotype of adeno-associated virus serotype 4
Govindasamy, L., Padron, E., McKenna, R., Muzyczka, N., Kaludov, N., Chiorini, J. A., & Agbandje-McKenna, M. (2006) · Journal of Virology · doi:10.1128/jvi.01536-06 · Cited by 205 · see citing works
Self-citationBleker, S., Sonntag, F., & Kleinschmidt, J. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.4.2528-2540.2005 · Cited by 200 · see citing works
Kronenberg, S., Böttcher, B., von der Lieth, C. W., Bleker, S., & Kleinschmidt, J. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.9.5296-5303.2005 · Cited by 198 · see citing works
Choi, J.-H., Yu, N.-K., Baek, G.-C., Bakes, J., Seo, D., Nam, H. J., Baek, S. H., Lim, C.-S., Lee, Y.-S., & Kaang, B.-K. (2014) · Molecular Brain · doi:10.1186/1756-6606-7-17 · Cited by 197 · see citing works
Structural Proteins of Adenovirus-Associated Viruses
Rose, J. A., Maizel, J. V., Inman, J. K., & Shatkin, A. J. (1971) · Journal of Virology · doi:10.1128/jvi.8.5.766-770.1971 · Cited by 190 · see citing works
Sonntag, F., Köther, K., Schmidt, K., Weghofer, M., Raupp, C., Nieto, K., Kuck, A., Gerlach, B., Böttcher, B., Müller, O. J., et al. (2011) · Journal of Virology · doi:10.1128/jvi.05359-11 · Cited by 184 · see citing works
Grieger, J. C., Snowdy, S., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.02723-05 · Cited by 172 · see citing works
Snijder, J., van de Waterbeemd, M., Damoc, E., Denisov, E., Grinfeld, D., Bennett, A., Agbandje-McKenna, M., Makarov, A., & Heck, A. J. R. (2014) · Journal of the American Chemical Society · doi:10.1021/ja502616y · Cited by 168 · see citing works
Self-citationGhosh, A., Yue, Y., Lai, Y., & Duan, D. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300322 · Cited by 161 · see citing works
Factors that bind to adeno-associated virus terminal repeats
Im, D. S., & Muzyczka, N. (1989) · Journal of Virology · doi:10.1128/jvi.63.7.3095-3104.1989 · Cited by 157 · see citing works
Wistuba, A., Weger, S., Kern, A., & Kleinschmidt, J. A. (1995) · Journal of Virology · doi:10.1128/jvi.69.9.5311-5319.1995 · Cited by 147 · see citing works
Structural Characterization of the Dual Glycan Binding Adeno-Associated Virus Serotype 6
Ng, R., Lakshmanan Govindasamy, A., Gurda, B. L., McKENNA, R. V., Kozyreva, O. G., Samulski, R. J., Parent, K. N., Baker, T. S., & Agbandje‐McKenna, M. (2010) · Journal of Virology · doi:10.1128/jvi.01235-10 · Cited by 143 · see citing works
Self-citationInsertional Mutagenesis of AAV2 Capsid and the Production of Recombinant Virus
Rabinowitz, J. E., Xiao, W., & Samulski, R. J. (1999) · Virology · doi:10.1006/viro.1999.0045 · Cited by 136 · see citing works
Adeno-Associated Virus Biology
Weitzman, M. D., & Linden, R. M. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_1 · Cited by 132 · see citing works
Cotmore, S. F., D’Abramo, A., Ticknor, C. M., & Tattersall, P. J. (1999) · Virology · doi:10.1006/viro.1998.9520 · Cited by 121 · see citing works
Structural Proteins of Adenovirus-Associated Virus Type 3
Johnson, F. B., Ozer, H. L., & HOGGAN, M. D. (1971) · Journal of Virology · doi:10.1128/jvi.8.6.860-863.1971 · Cited by 119 · see citing works
Characterization of adenovirus-associated virus-induced polypeptides in KB cells
Buller, R. M., & Rose, J. A. (1978) · Journal of Virology · doi:10.1128/jvi.25.1.331-338.1978 · Cited by 111 · see citing works
Heparin binding induces conformational changes in Adeno-associated virus serotype 2
Levy, H. C., Bowman, V. D., Govindasamy, L., McKenna, R., Nash, K., Warrington, K., Chen, W., Muzyczka, N., Yan, X., Baker, T. S., et al. (2009) · Journal of Structural Biology · doi:10.1016/j.jsb.2008.12.002 · Cited by 110 · see citing works
Self-citationRuffing, M., Zentgraf, H., & Kleinschmidt, J. A. (1992) · Journal of Virology · doi:10.1128/jvi.66.12.6922-6930.1992 · Cited by 109 · see citing works
Popa-Wagner, R., Porwal, M., Kann, M., Reuss, M., Weimer, M., Florin, L., & Kleinschmidt, J. A. (2012) · Journal of Virology · doi:10.1128/jvi.00282-12 · Cited by 109 · see citing works
The Rep52 Gene Product of Adeno-Associated Virus Is a DNA Helicase with 3′-to-5′ Polarity
Smith, R. H., & Kotin, R. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.6.4874-4881.1998 · Cited by 109 · see citing works
Earley, L. F., Powers, J. M., Adachi, K., Baumgart, J. T., Meyer, N. L., Xie, Q., Chapman, M. S., & Nakai, H. (2017) · Journal of Virology · doi:10.1128/jvi.01980-16 · Cited by 108 · see citing works
Assembly of adeno-associated virus
Myers, M. W., & Carter, B. J. (1980) · Virology · doi:10.1016/0042-6822(80)90071-9 · Cited by 107 · see citing works
Lerch, T. F., Xie, Q., & Chapman, M. S. (2010) · Virology · doi:10.1016/j.virol.2010.03.027 · Cited by 107 · see citing works
Ostedgaard, L. S., Rokhlina, T., Karp, P. H., Lashmit, P., Afione, S., Schmidt, M., Zabner, J., Stinski, M. F., Chiorini, J. A., & Welsh, M. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409845102 · Cited by 105 · see citing works
Adeno-Associated Virus Type 2 Protein Interactions: Formation of Pre-Encapsidation Complexes
Dubielzig, R., King, J., Weger, S., Kern, A., & Kleinschmidt, J. A. (1999) · Journal of Virology · doi:10.1128/jvi.73.11.8989-8998.1999 · Cited by 105 · see citing works
Koo, T., Popplewell, L., Athanasopoulos, T., & Dickson, G. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.164 · Cited by 104 · see citing works
Plus and Minus Single-Stranded DNA Separately Encapsidated in Adeno-Associated Satellite Virions
Mayor, H. D., Torikai, K., Melnick, J. L., & Mandel, M. (1969) · Science · doi:10.1126/science.166.3910.1280 · Cited by 100 · see citing works
Properties of the Adeno-Associated Virus Assembly-Activating Protein
Naumer, M., Sonntag, F., Schmidt, K., Nieto, K., Panke, C., Davey, N. E., Popa-Wagner, R., & Kleinschmidt, J. A. (2012) · Journal of Virology · doi:10.1128/jvi.01675-12 · Cited by 97 · see citing works
Structural insights into adeno-associated virus serotype 5
Govindasamy, L., DiMattia, M. A., Gurda, B. L., Halder, S., McKenna, R., Chiorini, J. A., Muzyczka, N., Zolotukhin, S., & Agbandje-McKenna, M. (2013) · Journal of Virology · doi:10.1128/jvi.00867-13 · Cited by 95 · see citing works
Self-citationGene Therapy of mdx Mice With Large Truncated Dystrophins Generated by Recombination Using rAAV6
Odom, G. L., Gregorevic, P., Allen, J. M., & Chamberlain, J. S. (2011) · Molecular Therapy · doi:10.1038/mt.2010.205 · Cited by 95 · see citing works
Hauck, B., Murphy, S. L., Smith, P. H., Qu, G., Liu, X., Zelenaia, O., Mingozzi, F., Sommer, J. M., High, K. A., & Wright, J. F. (2009) · Molecular Therapy · doi:10.1038/mt.2008.227 · Cited by 88 · see citing works
Little Vector, Big Gene Transduction: Fragmented Genome Reassembly of Adeno-associated Virus
Hirsch, M. L., Agbandje‐McKenna, M., & Samulski, R. J. (2010) · Molecular Therapy · doi:10.1038/mt.2009.280 · Cited by 86 · see citing works
Self-citationQiu, J., & Brown, K. E. (1999) · Virology · doi:10.1006/viro.1999.9664 · Cited by 86 · see citing works
Adeno-associated virus rep protein synthesis during productive infection
Redemann, B. E., Mendelson, E., & Carter, B. J. (1989) · Journal of Virology · doi:10.1128/jvi.63.2.873-882.1989 · Cited by 83 · see citing works
Lecomte, E., Tournaire, B., Cogné, B., Dupont, J.-B., Lindenbaum, P., Martin-Fontaine, M., Broucque, F., Robin, C., Hebben, M., Merten, O.-W., et al. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.32 · Cited by 83 · see citing works
Gao, G., Lü, Y., Sun, X., Johnston, J., Calcedo, R., Grant, R. L., & Wilson, J. M. (2006) · Journal of Virology · doi:10.1128/jvi.00526-06 · Cited by 78 · see citing works
Bleker, S., Pawlita, M., & Kleinschmidt, J. A. (2006) · Journal of Virology · doi:10.1128/jvi.80.2.810-820.2006 · Cited by 75 · see citing works
Structure–function analysis of receptor-binding in adeno-associated virus serotype 6 (AAV-6)
Xie, Q., Lerch, T. F., Meyer, N., & Chapman, M. S. (2011) · Virology · doi:10.1016/j.virol.2011.08.011 · Cited by 70 · see citing works
Colocalization of adeno-associated virus Rep and capsid proteins in the nuclei of infected cells
Hunter, L. A., & Samulski, R. J. (1992) · Journal of Virology · doi:10.1128/jvi.66.1.317-324.1992 · Cited by 68 · see citing works
Mietzsch, M., Casteleyn, V., Weger, S., Zolotukhin, S., & Heilbronn, R. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.050 · Cited by 65 · see citing works
Self-citationBevington, J. M., Needham, P. G., Verrill, K. C., Collaco, R. F., Basrur, V., & Trempe, J. P. (2007) · Virology · doi:10.1016/j.virol.2006.07.050 · Cited by 65 · see citing works
Design and Construction of Functional AAV Vectors
Gray, J. T., & Zolotukhin, S. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_2 · Cited by 63 · see citing works
Structure of neurotropic adeno-associated virus AAVrh.8
Halder, S., Vliet, K. V., Smith, J. K., Duong, T. T. P., McKENNA, R. V., Wilson, J. M., & Agbandje‐McKenna, M. (2015) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.08.017 · Cited by 62 · see citing works
Self-citationOversized AAV Transductifon Is Mediated via a DNA-PKcs-independent, Rad51C-dependent Repair Pathway
Hirsch, M. L., Li, C., Bellon, I., Yin, C., Chavala, S., Pryadkina, M., Richard, I., & Samulski, R. J. (2013) · Molecular Therapy · doi:10.1038/mt.2013.184 · Cited by 62 · see citing works
Wang, X. S., Qing, K., Ponnazhagan, S., & Srivastava, A. (1997) · Journal of Virology · doi:10.1128/jvi.71.4.3077-3082.1997 · Cited by 61 · see citing works
Assembly of adeno-associated virus type 2 capsids in vitro.
Steinbach, S., Kleinschmidt, J. A., Wistuba, A., & Bock, T. (1997) · Journal of General Virology · doi:10.1099/0022-1317-78-6-1453 · Cited by 52 · see citing works
Yoon-Robarts, M., Blouin, A. G., Bleker, S., Kleinschmidt, J. A., Aggarwal, A. K., Escalante, C. R., & Linden, R. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403900200 · Cited by 52 · see citing works
Drouin, L. M., Lins, B., Janssen, M., Bennett, A. D., Chipman, P. R., McKENNA, R. V., Chen, W., Muzyczka, N., Giovanni Cardone, A., Baker, T. S., et al. (2016) · Journal of Virology · doi:10.1128/jvi.00575-16 · Cited by 52 · see citing works
Self-citationNony, P., Chadeuf, G., Tessier, J., Moullier, P., & Salvetti, A. (2003) · Journal of Virology · doi:10.1128/jvi.77.1.776-781.2003 · Cited by 51 · see citing works
Ling, C., Wang, Y., Lu, Y., Wang, L., Jayandharan, G. R., Aslanidi, G. V., Li, B., Cheng, B., Ma, W., Lentz, T., et al. (2015) · Journal of Virology · doi:10.1128/jvi.02581-14 · Cited by 47 · see citing works
Atomic structure of viral particles
Chapman, M. S., & Agbandje‐McKenna, M. (2005) · CRC Press eBooks · doi:10.1201/b13393-13 · Cited by 47 · see citing works
Self-citationCotmore, S. F., & Tattersall, P. J. (2005) · Virology · doi:10.1016/j.virol.2005.03.007 · Cited by 44 · see citing works
Efficacy of Codelivery of Dual AAV2/5 Vectors in the Murine Retina and Hippocampus
Palfi, A., Chadderton, N., McKee, A. G., Blanco Fernandez, A., Humphries, P., Kenna, P. F., & Farrar, G. J. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.142 · Cited by 42 · see citing works
The structure of AAVrh32.33, a novel gene delivery vector
Mikals, K., Nam, H.-J., Vliet, K. V., Vandenberghe, L. H., Mays, L. E., McKENNA, R. V., Wilson, J. M., & Agbandje‐McKenna, M. (2014) · Journal of Structural Biology · doi:10.1016/j.jsb.2014.03.020 · Cited by 40 · see citing works
Self-citationRen, C.-C., Kumar, S., Shaw, D., & Ponnazhagan, S. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1047 · Cited by 32 · see citing works
Hüser, D., Weger, S., & Heilbronn, R. (2003) · Journal of Virology · doi:10.1128/jvi.77.8.4881-4887.2003 · Cited by 29 · see citing works
Nuclear translocation of adeno-associated virus type 2 capsid proteins for virion assembly
Popa-Wagner, R., Sonntag, F., Schmidt, K., King, J., & Kleinschmidt, J. A. (2012) · Journal of General Virology · doi:10.1099/vir.0.043232-0 · Cited by 24 · see citing works
Cassell, G. D., & Weitzman, M. D. (2004) · Virology · doi:10.1016/j.virol.2004.06.034 · Cited by 23 · see citing works
Altering Tropism of rAAV by Directed Evolution
Marsic, D., & Zolotukhin, S. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3271-9_11 · Cited by 12 · see citing works
Alex, M., Weger, S., Mietzsch, M., Slanina, H., Cathomen, T., & Heilbronn, R. (2012) · Journal of Virology · doi:10.1128/jvi.06364-11 · Cited by 9 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1016/j.jsb.2014.03.020 · DOI
Cited by
Sorted by citations
Twenty-Five Years of Structural Parvovirology
Mietzsch, M., Pénzes, J. J., & Agbandje-McKenna, M. (2019) · Viruses · doi:10.3390/v11040362 · Cited by 197 · see citing works
“The CPV structure confirmed the icosahedral nature of the parvovirus capsids with sixty VPs assembling one capsid via 2‐, 3‐, and 5‐fold symmetry related interactions [6,38,75].”
BackgroundSelf-citationDrug delivery systems for CRISPR-based genome editors
Madigan, V. J., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 180 · see citing works
“AAVs encapsulate a 4.7 kb-long single-stranded DNA genome containing two well-characterized open reading frames: Rep and Cap 44–46 .”
BackgroundInfluentialHołubowicz, R., Du, S. W., Felgner, J. H., Šmidák, R., Choi, E. H., Palczewska, G., Menezes, C. R., Dong, Z., Gao, F., Medani, O., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01296-2 · Cited by 102 · see citing works
“AAVs can typically accommodate genomes ~4.7 thousand base pairs long, which can be restrictive, especially when attempting to deliver larger genome-editing constructs such as base editing and prime editing systems 61–63 .”
InfluentialAAV vector development, back to the future
Suárez-Amarán, L., Song, L., Tretiakova, A. P., Mikhail, S., & Samulski, R. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.064 · Cited by 92 · see citing works
“32,36,44,50 The AAV capsid also contains five highly conserved basic region (BR) motifs: BR1, BR2, BR3, BR4, and BR5.”
Adeno-Associated Virus Genome Interactions Important for Vector Production and Transduction
Maurer, A. C., & Weitzman, M. D. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.069 · Cited by 65 · see citing works
“Specific residues on the lumenal surface of the capsid are known to make contact with the bases and backbone of the ssDNA genome in a sequence-independent manner.(76) Once the genome is packaged, it likely exerts a reasonable amount of force on the lumenal capsid surface.”
BackgroundHavlik, L. P., Simon, K. E., Smith, J. K., Klinc, K. A., Tse, L. V., Oh, D. K., Fanous, M. M., Meganck, R. M., Mietzsch, M., Kleinschmidt, J. A., et al. (2020) · Journal of Virology · doi:10.1128/jvi.00976-20 · Cited by 56 · see citing works
“Importantly, these clustered antigenic sites are reported to influence multiple functions, including attachment to cell surface glycans as well as AAVR, transduction efficiency, capsid assembly, and genome packaging in different AAV serotypes (18, 21, 22).”
BackgroundSelf-citationRational engineering of a functional CpG-free ITR for AAV gene therapy
Pan, X., Yue, Y., Boftsi, M., Wasala, L. P., Tran, N. T., Zhang, K., Pintel, D. J., Tai, P. W. L., & Duan, D. (2022) · Gene Therapy · doi:10.1038/s41434-021-00296-0 · Cited by 53 · see citing works
Improved Genome Packaging Efficiency of Adeno-associated Virus Vectors Using Rep Hybrids
Mietzsch, M., Eddington, C., Jose, A., Hsi, J., Chipman, P. R., Henley, T., Choudhry, M. S., McKENNA, R. V., & Agbandje‐McKenna, M. (2021) · Journal of Virology · doi:10.1128/jvi.00773-21 · Cited by 50 · see citing works
Self-citationAnalysis of AAV-Extracted DNA by Charge Detection Mass Spectrometry Reveals Genome Truncations
Barnes, L. F., Draper, B. E., Kurian, J. J., Chen, Y., Shapkina, T., Powers, T. W., & Jarrold, M. F. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c04234 · Cited by 41 · see citing works
A New Generation of Gene Therapies as the Future of Wet AMD Treatment
Błasiak, J., Pawłowska, E., Ciupińska, J., Derwich, M., Szczepanska, J., & Kaarniranta, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042386 · Cited by 24 · see citing works
“The AAV genome has 4.8 kb of ssDNA and two T-shaped inverted terminal repeats (ITRs), on either end of the genome [41] (Figure 2).”
BackgroundInfluentialPark, S.-J., Shin, S., Lee, H., Jang, J., & Lee, G. M. (2024) · Biotechnology Journal · doi:10.1002/biot.202300667 · Cited by 28 · see citing works
Genome-wide activation screens to increase adeno-associated virus production
Barnes, C. R., Lee, H., Ojala, D. S., Lewis, K. K., Limsirichai, P., & Schaffer, D. V. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.06.026 · Cited by 28 · see citing works
“AAV packaging efficiency in producer cell lines Following viral genome replication, the lower molecular weight Rep proteins promote genome encapsidation into AAV virion to generate 98 Molecular Therapy: Nucleic Acids Vol. 26 December 2021 infectious AAV.35 We examined whether increased AAV vector genome replication ma…”
InfluentialProduction and characterization of an AAV1-VP3-only capsid: An analytical benchmark standard
Mietzsch, M., Liu, W., Ma, K., Bennett, A. D., Nelson, A. R., Gliwa, K., Chipman, P. R., Fu, X., Bechler, S. L., McKENNA, R. V., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.05.002 · Cited by 28 · see citing works
“The AAV vectors are composed of a single-stranded DNA transgene expression cassette packaged into the T = 1 icosahedral protein capsid.(10) The capsids are 26 nm in diameter and assembled from 60 viral proteins (VPs).”
BackgroundSelf-citationPais, D. A. M., Galrão, P. R. S., Kryzhanska, A., Barbau, J., Isidro, I. A., & Alves, P. M. (2020) · Processes · doi:10.3390/pr8040487 · Cited by 25 · see citing works
“Additionally, AAV capsid assembly takes place in the nucleolus [38].”
BackgroundEmerging Perspectives on Gene Therapy Delivery for Neurodegenerative and Neuromuscular Disorders
Limia, C. E. G., Baird, M., Schwartz, M., Saxena, S., Meyer, K., & Wein, N. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12121979 · Cited by 23 · see citing works
“The third plasmid (pAAV helper) carries the genes encoding critical proteins that allow the virus to propagate [33] (Figure 1C).”
BackgroundStructural Characterization of Cuta- and Tusavirus: Insight into Protoparvoviruses Capsid Morphology
Mietzsch, M., McKENNA, R. V., Väisänen, E., Yu, J. C., Ilyas, M., Hull, J. A., Kurian, J. J., Smith, J. K., Chipman, P. R., Lasanajak, Y., et al. (2020) · Viruses · doi:10.3390/v12060653 · Cited by 20 · see citing works
“In the icosahedral capsid the VPs assemble utilizing 2-, 3-, and 5-fold symmetry-related VP interactions [8].”
BackgroundSelf-citationWang, Y., Fu, Q., Park, S. Y., Lee, Y. S., Park, S., Lee, D., & Yoon, S. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108322 · Cited by 19 · see citing works
Hoad, M., Cross, E. M., Donnelly, C. M., Sarker, S., Roby, J. A., & Forwood, J. K. (2023) · Viruses · doi:10.3390/v15020315 · Cited by 17 · see citing works
“The Cap gene of AAV encodes three capsid proteins that share a C-terminal sequence and combine to form the shell-like outer structure of the virus [37,38].”
BackgroundStructural Study of Aavrh.10 Receptor and Antibody Interactions
Mietzsch, M., Yu, J. C., Hsi, J., Chipman, P. R., Broecker, F., Fuming, Z., Linhardt, R. J., Seeberger, P. H., Heilbronn, R., McKenna, R., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01249-21 · Cited by 16 · see citing works
Self-citationXiang, Y. S., & Hao, G. G. (2023) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-023-00518-5 · Cited by 17 · see citing works
“Mutational studies showed that the VP3 sequence is sufficient for the assembly of AAV capsids by knocking out the start codons of VP1 and VP2 [60].”
BackgroundInfluentialBiophysical and structural insights into AAV genome ejection
Gliwa, K., Hull, J. A., Kansol, A., Zembruski, V., Lakshmanan, R., Mietzsch, M., Chipman, P. R., Bennett, A. D., & McKENNA, R. V. (2025) · Journal of Virology · doi:10.1128/jvi.00899-24 · Cited by 16 · see citing works
“A defective genome packaging or retention phenotype is also associated with several fivefold variants (18, 27).”
Self-citationThe Expression and Function of the Small Nonstructural Proteins of Adeno-Associated Viruses (AAVs)
Küz, Ç. A., McFarlin, S., & Qiu, J. (2024) · Viruses · doi:10.3390/v16081215 · Cited by 15 · see citing works
“The capsid is assembled in the nucleoli followed by the VP1u and VP2u NLS-mediated input of the cytoplasmic trimerized structural proteins [85–87].”
BackgroundTherapeutic Application and Structural Features of Adeno-Associated Virus Vector
Matsuzaka, Y., & Yashiro, R. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46080499 · Cited by 15 · see citing works
“The VP composition ratio of the AAV2 capsid is estimated to be VP1 (82 kDa)/VP2 (65 kDa)/VP3 (60 kDa) = 1:1:10 in terms of molar ratio, but individual capsid composition is divergent and stochastic due to mosaicism [4,13,27].”
BackgroundInfluentialCatalán-Tatjer, D., Tzimou, K., Nielsen, L. K., & Lavado‐García, J. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108370 · Cited by 14 · see citing works
Ye, X., Hu, Y., Qiu, H., & Li, N. (2024) · Protein Science · doi:10.1002/pro.5074 · Cited by 13 · see citing works
Thakur, G., Mink, S. R., Garcia, A. J., Bak, H., & Tustian, A. D. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101441 · Cited by 12 · see citing works
Mietzsch, M., Hsi, J., Nelson, A. R., Khandekar, N., Huang, A.-M., Smith, N. J. C., Zachary, J., Potts, L., Farrar, M. A., Chipman, P. R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59088-4 · Cited by 15 · see citing works
“How is this explained? hAEV6 and AAV9 differ in infectivity.”
Self-citationIn vivo delivery systems for CRISPR genome editing: Viral and non-viral carriers
Lee, Y., Kim, B., Lee, D., Cheon, S. Y., Lim, S. G., Kim, Y., & Koo, H. (2025) · Applied Physics Reviews · doi:10.1063/5.0228874 · Cited by 12 · see citing works
Steininger, T., Öttl, V., Franken, L. E., Frank, C., Ohland, P., Ferreiro, M., Klostermann, S., Fritsch, J., Hirschauer, E., Sandmeir, A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031319 · Cited by 10 · see citing works
“The answer might be found in the kinetics of vector amplification or the superiority of particle production with Rep 2.41, which results in more viral capsids available for packaging viral genomes—a process known to occur post-assembly [68].”
InfluentialAdeno-associated viruses for efficient gene expression in the axolotl nervous system
Lust, K., & Tanaka, E. M. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2421373122 · Cited by 9 · see citing works
Hoad, M., Roby, J. A., & Forwood, J. K. (2021) · FEBS Letters · doi:10.1002/1873-3468.14209 · Cited by 10 · see citing works
Tworig, J. M., Grafton, F., Fisher, K., Hörer, M., Reid, C. A., & Mandegar, M. A. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101384 · Cited by 10 · see citing works
Townsend, J. A., Li, S., Sweezy, L., Liu, N., Rosconi, M. P., Pyles, E. A., Zhi, L., Liu, D., Wu, Z., Qiu, H., et al. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.01.005 · Cited by 9 · see citing works
Park, S.-J., Shin, S., Han, G., & Lee, G. M. (2025) · Biotechnology Journal · doi:10.1002/biot.202400529 · Cited by 9 · see citing works
“Since AAVs utilize the host cell’s machinery for replication, apoptosis signals can significantly hinder AAV production [19, 20].”
DNA Satellites Impact Begomovirus Diseases in a Virus-Specific Manner
Fondong, V. N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125814 · Cited by 9 · see citing works
“In ssRNA viruses, for example, packaging proteins specifically recognize and bind to the stem–loop with high affinity, followed by encapsidation of only its genetic material [35–40].”
Quantitative analysis of preferential utilization of AAV ITR as the packaging terminal signal
Li, X., Miller, L. M., Chrzanowski, M., Tian, J., Jarrold, M. F., Herzog, R. W., Xiao, W., Draper, B. E., & Zhang, J. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1327433 · Cited by 9 · see citing works
Lopes, J. A., Garnier, N. E., Pei, Y., Yates, J. G. E., Campbell, E. S. B., Goens, M. M., Hughes, M. E., Rghei, A. D., Stevens, B. A. Y., Guilleman, M. M., et al. (2024) · Gene Therapy · doi:10.1038/s41434-024-00453-1 · Cited by 9 · see citing works
“This increase in size meant that we could not fi t the MEDI3902 gene into an AAV genome encoding a CASI promoter and a full-size WPRE, as this would surpass the ~4.7 kb packaging limit [41].”
InfluentialThe amazing AAV capsids: Into the structure-verse
Hsi, J., Mietzsch, M., & McKENNA, R. V. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101629 · Cited by 8 · see citing works
Self-citationStructural basis for nuclear import of bat adeno-associated virus capsid protein
Hoad, M., Roby, J. A., & Forwood, J. K. (2024) · Journal of General Virology · doi:10.1099/jgv.0.001960 · Cited by 7 · see citing works
“These three VP proteins coalesce to form the capsid of AAV in a ratio of 1 : 1 : 10 (VP1:VP2:VP3) [51, 52].”
BackgroundAdeno-Associated Virus 5 Protein Particles Produced by E. coli Cell-Free Protein Synthesis
Deuker, D., Asilonu, E., Bracewell, D. G., & Frank, S. (2024) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00403 · Cited by 6 · see citing works
Schrecke, S. R., McManus, K. T., Moshfegh, C., et al. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1436857 · Cited by 6 · see citing works
“AAV yield per cell is dependent upon i) plasmid or helper co-infection and internalization, ii) rate of AAV-related protein and DNA synthesis, iii) their packaging ef fi ciency, and iv) assembly inside the infected cell (Wang et al., 2015; Bennett et al., 2017).”
BackgroundInfluentialPolo-like kinase inhibitors increase AAV production by halting cell cycle progression
Fisher, K., Grafton, F., Ispaso, F., Tworig, J. M., Derler, R., Sonntag, F., Hörer, M., Schulze, A., Reid, C. A., & Mandegar, M. A. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101412 · Cited by 6 · see citing works
Structural Capsidomics of Single-Stranded DNA Viruses
Mietzsch, M., Bennett, A. D., & McKENNA, R. V. (2025) · Viruses · doi:10.3390/v17030333 · Cited by 6 · see citing works
“For the ssDNA viruses with known capsid structures, strategy I has been suggested for the Geminiviridae , Bacilladnaviridae , Finnlakeviridae , and Ficleduovirus [20,21,91,92], whereas the Microviridae and Parvoviridae utilize strategy II [30,51,93,94].”
Self-citationConnexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy
Zhang, J., Zanella, F., Ellis, M. W., Bradford, W. H., Gutierrez-Lara, E. J., Wang, T.-M., Fujita, K., Duron, C., Karakikes, I., Lyon, R. C., et al. (2026) · Circulation: Heart Failure · doi:10.1161/circheartfailure.125.013801 · Cited by 5 · see citing works
Production of VP3-only virus-like particles of Adeno-associated virus 2 in E. coli cells
Fu, C., Gobbooru, S., Martino, A. T., & Low, W. (2024) · Protein Expression and Purification · doi:10.1016/j.pep.2024.106502 · Cited by 4 · see citing works
Stabilization of a single-stranded DNA of adeno-associated virus by inverted terminal repeats
Yuan, Y.-Z., Higashiyama, K., Ito-Kudo, E., Masumi-Koizumi, K., Yusa, K., & Uchida, K. (2024) · Scientific Reports · doi:10.1038/s41598-024-78612-y · Cited by 5 · see citing works
“AAV ITRs play a pivotal role in the processes of replication, encapsidation, and integration of the viral genome into the host genome 22 .”
Frenkel, R., Tribby, D., Boumajny, B., Larson, N. R., Sampson, M., Barney, C., Bergelson, S., Sosic, Z., & Yeung, B. (2022) · The AAPS Journal · doi:10.1208/s12248-022-00768-0 · Cited by 4 · see citing works
“7 kb, but variability in packaging efficiency can lead to overpacked or partially filled particles, where the gene of interest is not packaged at exactly one copy per particle as intended (6).”
BackgroundSchildgen, O., Qiu, J., Mietzsch, M., Allander, T., Jartti, T. T., Schildgen, V., Grimm, D., & Söderlund‐Venermo, M. (2025) · Clinical Microbiology Reviews · doi:10.1128/cmr.00173-24 · Cited by 3 · see citing works
“10), which connect the interior of the capsid to the exterior environment and likely represents the route of genome packaging for the capsid (312, 313).”
Self-citationFong, S., Swystun, L. L., Batty, P. A., & Lillicrap, D. (2026) · Therapeutic Advances in Hematology · doi:10.1177/20406207251406537 · Cited by 3 · see citing works
“20 Hemophilia gene therapies use a number of naturally occurring AAV capsid serotypes as well as bioengineered proprietary variants.”
Wang, X.-S., Yang, Z., Pla, A., Ng, M., Zhuang, B., Ahuja, S., Tjoanda, C., Purde, V., Wenzel, S., Marshall, B., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101579 · Cited by 3 · see citing works
Evaluating management strategies to control geminivirus
Vargas-Hernández, M., Rivero-Montejo, S. D. J., Macias-Bobadilla, I., et al. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90587-9.00037-7 · Cited by 3 · see citing works
CapBuild: a cloud-native tool for adeno-associated virus capsid engineering
Klein, A. H., Kuiper, M. J., Burgess, M., Wickramarachchi, A., Jain, Y., Bauer, D. C., & Wilson, L. O. W. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf422 · Cited by 3 · see citing works
“The capsid shell consists of 60 copies of three Viral Protein (VP) sub-units (VP1, VP2 and VP3), existing in a specific ratio and arranged in strict symmetry [ 8 , 9 ].”
Mietzsch, M., Nelson, A. R., Hsi, J., Zachary, J., Potts, L., Chipman, P. R., Ghanem, M., Khandekar, N., Alexander, I. E., Logan, G. J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.01.590489 · Cited by 3 · see citing works
Self-citationBhadury, R., Athar, M. S., Mishra, P., Gogoi, C., Sharma, S., & Ghorpade, D. S. (2025) · Cells · doi:10.3390/cells14050372 · Cited by 2 · see citing works
Ye, X., Hu, M., Hu, Y., Qiu, H., & Li, N. (2025) · Gene Therapy · doi:10.1038/s41434-025-00539-4 · Cited by 2 · see citing works
“The fi ve-fold channel has been indicated to be the gateway through which DNA cargo is packed into and released from the capsid [18, 51].”
hafoe: an interactive tool for the analysis of chimeric AAV libraries after random mutagenesis
Jalatyan, T., Aznauryan, E. I., Hasan, R., Vardanyan, V., Nersisyan, S. A., Thompson, D. B., Davidsohn, N., Thomas, S., van Haren, S. D., Tam, J. M., et al. (2025) · Gene Therapy · doi:10.1038/s41434-025-00548-3 · Cited by 2 · see citing works
“The AAV genome encodes non-structural ( rep ), structural ( cap ), assembly activating ( aap ), and membrane-associated accessory ( maap ) proteins [9].”
The Coming of Age of Gene Therapy for the Treatment of Human Diseases: A Regulatory Perspective
Rodríguez, L., de Felipe, P., Martín, R., Martínez, J., Ordóñez, D., Rojo, S., Martínez, J. F., Rincón, E., Cejalvo, T., Izquierdo, I., et al. (2025) · Human Gene Therapy · doi:10.1177/10430342251372047 · Cited by 2 · see citing works
Mosaic AAV mediates efficient transduction across the central and peripheral nervous systems
Jiang, M., Yin, W., Mo, X., Wang, Z., Qiu, M. S., & Dai, Z. (2025) · Molecular Brain · doi:10.1186/s13041-025-01270-2 · Cited by 2 · see citing works
“The AAV capsid consists of 60 overlapping subunits of VP1, VP2, and VP3, with VP3 primarily determining serotype-specific receptor binding characteristics [24, 25].”
Yu, L., Zhou, Y. F., Shi, X., Wang, G., Fu, Z., Liang, C., & Wang, J. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101304 · Cited by 1 · see citing works
Chen, Q., Lee, C. H., Whitfield, R., & Nesbeth, D. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101610 · Cited by 1 · see citing works
Ren, H., Nie, J., Song, Z., Mo, W., Yang, Y., & Bai, Z. (2026) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2025.12.018 · Cited by 1 · see citing works
“As biosynthesis of AAV is a complex process, we speculate that additional steps such as genome processing, genome encapsidation, and virion release may affect AAV production as well [16,42,43].”
In vivo CAR-T for the treatment of autoimmune diseases: Current progress and future directions
Zhao, Y., Liu, Y., Peng, X., Ma, X., & Yang, Q. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102245 · Cited by 1 · see citing works
“51,52 Consequently, while AAV-mediated in vivo CAR production is functionally viable and highly appealing, its clinical applicability remains contingent upon further engineering and clinical validation to address the risks associated with carrier capacity, immunogenicity, dosage, and…”
Recent advances of CRISPR-based gene editing technologies and delivery strategies
Xue, F., Xin, Z., Wang, G., Xing, J., Han, H., Zhao, X., & Song, N. H. (2026) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2026.2702869 · Cited by 1 · see citing works
Optimization of Production of Recombinant Adeno-Associated Virus Serotype 9
Aliev, T. I., & Рамисович, И. И. (2025) · Molecular Biology · doi:10.1134/s0026893325700244 · Cited by 1 · see citing works
Structural and Functional Characterization of Porcine Adeno-Associated Viruses
Nelson, A. R., Mietzsch, M., Hsi, J., Eby, J., Chipman, P. R., & McKENNA, R. V. (2025) · Viruses · doi:10.3390/v17091260 · Cited by 1 · see citing works
Self-citationNaskar, R., Pal, P., Parsa, K. V. L., Paul, B., Oruganti, S., & Chakraborty, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148553 · Cited by 2 · see citing works
Jiang, Z., Laosinwattana, S., & Dalby, P. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.24.666527 · Cited by 1 · see citing works
Synthetic Type III-E CRISPR-Cas Effectors for Programmable RNA-targeting
Brogan, D. J., Lin, C. P., Benetta, E. D., Wang, T., Chen, F., Li, H., Lin, C., Komives, E. A., & Akbari, O. S. (2026) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169566 · Cited by 4 · see citing works
Identification of Adeno-associated Virus in Muscovy Ducks with Chronic Diarrhea
Sallam, H. M., & Zanaty, A. M. (2022) · Journal of World s Poultry Research · doi:10.36380/jwpr.2022.25
Winston, S. M., Brimble, M. A., Wiggins, K., Reeves, I. L., Spence, Y., Fan, B., Tan, S., Morton, C. L., Cheng, P.-H., Spence, M. Y., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201680
“53,54 Finally, to ensure that the modified p5 promoters did not impact functionality, we delivered AAV8 vectors carrying an FVIII trans-gene and saw no difference in circulating protein 1 week after gene transfer between vectors produced with WT p5, DI GC, and TRS5 promoters (Figure S6A).”
Schrama, M., Cabosart, D., Daniel, Y., Bakker, A., de Jong, L. A., Puri, P., Hoeksema, F., Pijlman, G. P., van Oers, M. M., Wijffels, R. H., et al. (2026) · New Biotechnology · doi:10.1016/j.nbt.2026.02.006
Muto, K., Sajiki, A. F., Goto, K., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-46464-3
“The EYS gene exceeds the 4.7 kb packaging capacity of conventional adeno-associated virus (AAV) vectors 42,43 , rendering EYS -RP unsuitable for conventional AAV-mediated gene therapy.”
InfluentialEtude des réponses T CD8+ après transfert de gène par rAAV ciblant le muscle
Jeanpierre, L. (2024) · theses.fr (ABES) · doi:10.70675/430aceacz50d2z426bz907dz876c55d1e935
Nishimura, Y., Hataya, S., Saito, S., & Makita, N. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.22.720036
RNA sensors and actuators for dynamic cellular regulation
Stohr, A. M., Hansen, H., Ma, D., Blenner, M., & Chen, W. (2026) · Trends in biotechnology · doi:10.1016/j.tibtech.2026.04.005
Sha, S., Hossler, P., Abrahamyan, A., et al. (2026) · Biotechnology Progress · doi:10.1002/btpr.88524
“18 Interestingly, capsid production, gene amplification, and genome encapsidation for rAAV were”
Omics-guided engineering of CHO cells reveals host targets to support AAV production
Tzimou, K., López-García, G., Sipahi, M. İ., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201771
“25,26 This nuclear localization aligns with our findings showing that many of the identified proteins are associated with nuclear functions and transcriptional regulation.”
Status and future of recombinant adeno‐associated virus vector manufacturing
Agbogbo, F., & Dismuke, D. J. (2026) · Biotechnology Progress · doi:10.1002/btpr.88525
Why architecture matters: Controlling gene expression through designPreprint
Gupta, A., & Lewis, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.06.743186
“All constructs were maintained below 4,274 bp from the 5 ′ to 3 ′ ITR, within the approximately 4.7-kb AAV genome packaging capacity [22] (Fig.”
InfluentialGene therapies (2015–2025): determinants of translational success
Sackett, J., Jaber, S., Gangapur, P., Biernat, M., & Bao, S. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118450
Celesti, F. (2026) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2026.105078
Polazzo, G., Schwarzer, M., & Hubbuch, J. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1913731
- Authors
- Bennett, A., Mietzsch, M., & Agbandje-McKenna, M.
- Affiliations
- University of Florida (US)
- Department of Biochemistry & Molecular Biology Center for Structure Biology McKnight Brain Institute University of Florida Gainesville FL 32610-0245 USA
- Venue
- Future Virology
- Publisher
- Informa UK Limited
- Published
- 2017-06
- Volume
- 12
- Issue
- 6
- Pages
- 283-297
- ISSN
- 1746-0794 (ISSN-L)
- 1746-0808
- PMC
- PMC9910337
- OpenAlex
- W2623463662
- Cited by
- 82
- References
- 85
- Citations by year
- 2026: 17 · 2025: 27 · 2024: 18 · 2023: 6 · 2022: 4 · 2021: 5 · 2020: 4 · 2019: 1
- FWCI
- 0.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Future Virology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5r01gm082946-15)
- National Institute of General Medical Sciences (R01GM109524, R01 GM-082946)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- adeno-associated virus, capsid assembly, genome packaging, adeno-associated virus vectors, VP1, VP2, VP3, inverted terminal repeats, packaging capacity, vector engineering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-28.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-28.
Cited sources are checked by gpt-6-sol.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review